Rusan Pharma has achieved a significant global milestone by receiving Good Manufacturing Practice (GMP) approval from Pharmaceuticals and Medical Devices Agency (PMDA), one of the world’s most stringent drug regulators.
World Liver Day 2026 highlights a growing concern—liver damage is no longer driven by alcohol alone.Experts say everyday choices around food, sleep, and stress are now major contributors to declining liver health.
Roche has announced a fresh clinical push for its gene therapy as it rolls out a new Elevidys study aimed at addressing concerns raised by European regulators. The move comes after the therapy failed to secure approval in Europe, prompting the...
A new study has raised concerns about how reliable AI chatbots are when it comes to providing medical information. The research found that many of their responses can be inaccurate medical advice or incomplete, which could mislead users seekin...
As India’s biotechnology sector enters a high-growth phase, a key question is emerging: can it deliver breakthrough therapies globally? In the latest episode of the “What India Needs!” podcast, host Shutapa Paul spoke with Dr Jogin Desai, Found...
The US Food and Drug Administration has asked Eli Lilly to submit additional safety data for its newly approved weight-loss pill, Foundayo, even as the drug begins entering the market.
India’s homeopathy industry is seeing a steady rise in global demand, supported by the government’s push to improve quality standards through the AYUSH Premium Mark initiative. Experts believe this move is helping build trust in Made in Indi...
AbbVie has shared promising results from a Phase 2 clinical trial testing a new combination treatment for ovarian cancer, offering fresh hope for patients with limited options.
AstraZeneca Pharma has secured a key Calquence approval in India, receiving clearance from the Central Drugs Standard Control Organisation to import and distribute Acalabrutinib tablets 100 mg under the brand name Calquence.
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has reported encouraging results from its Phase 3 clinical trial of BP11 biosimilar, a biosimilar to the widely used biologic drug Xolair (omalizumab). The announcement marks a key milesto...
.jpg)
, CDSCO.jpg)